Zobrazeno 1 - 3
of 3
pro vyhledávání: '"van Roy AAMGP"'
Autor:
Zeverijn LJ; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands., van Waalwijk van Doorn-Khosrovani SB; CZ Health Insurance, Tilburg, Netherlands., van Roy AAMGP; CZ Health Insurance, Tilburg, Netherlands., Timmers L; National Health Care Institute (Zorginstituut Nederland), Diemen, Netherlands., Ly Tran TH; National Health Care Institute (Zorginstituut Nederland), Diemen, Netherlands., de Boer JE; National Health Care Institute (Zorginstituut Nederland), Diemen, Netherlands., de Wit GF; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands., Geurts BS; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands., Verheul HMW; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands., Blijlevens N; Department of Hematology, Radboud University Medical Center, Nijmegen, Netherlands., Wymenga ANM; Department of Medical Oncology, Medical Spectrum Twente, Enschede, Netherlands., Eskens FALM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, Netherlands., Bloemendal HJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands., Voest EE; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands; Oncode Institute, Utrecht, Netherlands. Electronic address: e.voest@nki.nl.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2022 Feb; Vol. 23 (2), pp. 198-201.
Autor:
Christopoulos, Petros, Schlenk, Richard, Kazdal, Daniel, Blasi, Miriam, Lennerz, Jochen, Shah, Rajiv, Budczies, Jan, Malek, Nisar, Fröhling, Stefan, Rosenquist, Richard, Schirmacher, Peter, Bozorgmehr, Farastuk, Kuon, Jonas, Reck, Martin, Thomas, Michael, Stenzinger, Albrecht
Publikováno v:
Genes, Chromosomes & Cancer; Sep2023, Vol. 62 Issue 9, p557-563, 7p
Autor:
Edsjö A; Department of Clinical Genetics, Pathology and Molecular Diagnostics, Office for Medical Services, Region Skåne, Lund, Sweden.; Division of Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.; Genomic Medicine Sweden (GMS), Kristianstad, Sweden., Holmquist L; Department of Clinical Genetics, Pathology and Molecular Diagnostics, Office for Medical Services, Region Skåne, Lund, Sweden.; Genomic Medicine Sweden (GMS), Kristianstad, Sweden., Geoerger B; Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.; INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France., Nowak F; Health Technologies Institute, Inserm, Paris, France., Gomon G; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands., Alix-Panabières C; Laboratory of Rare Human Circulating Cells, University Medical Center of Montpellier, Montpellier, France.; CREEC, MIVEGEC, University of Montpellier, Montpellier, France., Ploeger C; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.; Centers for Personalized Medicine (ZPM), Heidelberg, Germany., Lassen U; Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark., Le Tourneau C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.; INSERM U900 Research Unit, Saint-Cloud, France.; Faculty of Medicine, Paris-Saclay University, Paris, France., Lehtiö J; Department of Oncology Pathology, Karolinska Institutet, Science for Life Laboratory, Stockholm, Sweden., Ott PA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., von Deimling A; Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany., Fröhling S; Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Voest E; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Klauschen F; Institute of Pathology, Charite - Universitätsmedizin Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.; BIFOLD - Berlin Institute for the Foundations of Learning and Data, Berlin, Germany.; Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Munich Partner Site, Heidelberg, Germany., Dienstmann R; Oncoclínicas Precision Medicine, Oncoclínicas Group, Sao Paulo, Brazil., Alshibany A; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Siu LL; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Stenzinger A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.; Centers for Personalized Medicine (ZPM), Heidelberg, Germany.
Publikováno v:
Journal of internal medicine [J Intern Med] 2023 Oct; Vol. 294 (4), pp. 455-481. Date of Electronic Publication: 2023 Aug 28.